Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
AstraZeneca stock gapped higher Friday as cancer drugs Enhertu and Tagrisso lent themselves to a solid third-quarter report. The post AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential appeared first on Investor’s Business Daily.
AbbVie stock slipped slightly Friday, but the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi. The post AbbVie’s Earnings Double As Immunology Powerhouse Skyrizi Beats Again appeared first on Investor’s Business Daily.
Regeneron stock popped Thursday after its Sanofi-partnered allergic conditions drug, Dupixent, easily beat third-quarter calls. The post Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts appeared first on Investor’s Business Daily.
Gilead Sciences crushed Wall Street’s sales expectations on the back of its HIV treatments and cancer drug Trodelvy. The post How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade appeared first on Investor’s Business…
Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions for its experimental lung cancer treatment. The post Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist appeared first on Investor’s Business Daily.
Bristol Myers Squibb stock dipped early Thursday on lighter-than-expected Opdivo sales and an earnings guidance haircut. The post Bristol Myers Slips: Opdivo Sales Come Up Short, Earnings Guidance Cut appeared first on Investor’s Business Daily.
Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound. The post Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance appeared first on Investor’s Business Daily.
Dow Jones component Merck hiked its 2026 outlook Thursday on the back of a solid third-quarter report that included a notable Keytruda beat. The post Merck Beats, But Can Shares Outplay The Cancer Vaccine News? appeared first on Investor’s Business…
Hims stock popped Wednesday after RFK Jr. circumvented the FDA, giving a green light to some unapproved peptides. The post Hims Stock Surges After RFK Jr. Eases Access To Unapproved Peptides appeared first on Investor’s Business Daily.
Eli Lilly’s next-generation weight-loss drug, retatrutide, trounced Novo’s Ozempic in a head-to-head study, the company said Wednesday. The post Eli Lilly’s Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test appeared first on Investor’s Business Daily.